Health ❯ Healthcare ❯ Clinical Trials ❯ Drug Efficacy

Weight Loss Medications

Wearable Data Show People Move Less After Starting GLP‑1 Weight‑Loss Drugs

ENDO 2026 presentations link the activity drop to greater risk of lean muscle loss and call for prescribing structured exercise with GLP‑1 therapy.

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

New Evidence Flags Rapid Weight Regain After Stopping GLP-1 Drugs

Pfizer to Buy Metsera for $4.9 Billion Upfront in Return to Obesity Drugs